Home » Blog » Which Biopharmaceutical Companies Are Big Spenders?

Which Biopharmaceutical Companies Are Big Spenders?

IP Blog | Dave Melin | September 18, 2016

BioBlog Weekly

This week’s BioBlog is stocked full of interesting articles on Big Data in Cancer, NCNC Appropriate Use Criteria, the Voice of the Patient, CMS Eases MACRA Timeline, and much more.

Top 15 Immuno-Oncology Collaborations

Which Biopharmas Have Spent the Most on Cancer Immunotherapy Partnerships?

This article from GEN explains, “With the potential for billions in new revenues, biopharma giants have proven willing to shell out billions in collaborations with smaller biotechs aimed at developing new immunotherapies for cancer”.

Voices of Patients and Oncologists Must be Heard, Study Says

Learn about the results of a study in which both the patients and oncologists received specialized communication training.

The Oncology Drug Pipeline Shows No Evidence of Slowing Down

In this article, we look at positive findings associated with many investigational therapies, including therapies for the treatment of patients with B-cell malignancies or acute myeloid leukemia (AML); a vaccine for the treatment of patients with AML; and a chimeric monoclonal antibody a for the treatment of patients with advanced gastric cancers.

NCCN Imaging Appropriate Use Criteria to be Integrated into New Century Health’s Oncology Clinical Decision Support Platform

“We strongly believe that expanding our strategic collaboration with NCCN strengthens our ability to bring enhanced clinical value to oncologists,” said Atul Dhir, MD, DPhil, Chief Executive Officer, New Century Health.

CMS Eases MACRA Quality Payment Program Timeline

Acting CMS Administrator Andy Slavitt lays out four pathways to compliance with the new Quality Payment Program (in order of easiest to the hardest).  

New Big Data Approach Predicts Drug Toxicity in Humans

“We looked more broadly at drug molecule features that drug developers thought were unimportant in predicting drug safety in the past. Then we let the data speak for itself,” said author Dr. Olivier Elemento.

Cost of Chemotherapy for Breast Cancer Varies Widely Across Regimens

Understanding the costs of care may be particularly relevant for patients who can choose among several guideline-concordant adjuvant chemotherapy regimens of similar efficacy, suggested Sharon H. Giordano, MD, MPH, Department Chair, Department of Health Services Research, M.D. Anderson Cancer Center, Houston, TX.


Topics in this Post:

Leave a Comment

Your email address will not be published. Required fields are marked *